The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States

Table 1

Moderate hypofractionation trials.

Trial	Design	pts randomized	Patient population (NCCN)	Fractionation and Total dose	5-year FFF^1 rate
CHHiP	Non-inferiority	3216	73% IR^2	37 X 2Gy, 74GY; 20 X 3Gy, 60Gy; 19 X 3Gy, 57Gy	88.3%; 90.6%; 85.9%
PROFIT	Non-inferiority	1206	100% IR	39 X 2Gy, 78Gy; 20 X 3Gy, 60Gy	79%; 79%
RTOG 0415	Non-inferiority	1092	100% LR^3	41 X 1.8Gy, 73.8Gy; 28 X 2.5Gy, 70Gy	85.3%; 86.3%
HYPRO	Superiority	804	73% HR^4	39 X 2Gy, 78GY; 19 X 3.4Gy, 64.6Gy	77%; 81%
Pollack et al.	Superiority	303	64% HR	38 X 2Gy, 76Gy; 26 X 2.7GY, 70.2Gy	85%; 81%
Arcangeli et al.	Superiority	168	76% HR	40 X 2Gy, 80Gy; 20 X 3.1Gy, 62Gy	79%; 85%
Hoffman et al	Superiority	204	70% IR	42 X 1.8Gy, 75.6GY; 30 X 2.4Gy, 72Gy	92%; 96%

: freedom from failure.
²IR: intermediate risk.
³LR: low risk.
⁴HR: high risk.